{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Octreotide+%28drug%29&page=3", "query": { "intervention": "Octreotide (drug)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 131, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Octreotide+%28drug%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Octreotide+%28drug%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T21:53:16.834Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05050942", "title": "A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-enteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "CAM2029", "type": "DRUG" }, { "name": "Octreotide LAR", "type": "DRUG" }, { "name": "Lanreotide ATG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Camurus AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2021-10-22", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-05T21:53:16.834Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Santa Monica, California • Denver, Colorado + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05050942" }, { "nct_id": "NCT01619865", "title": "Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Carcinoid Tumors", "Neuroblastoma", "Medulloblastoma" ], "interventions": [ { "name": "68Ga-DOTATOC PET/CT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sue O'Dorisio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 223, "start_date": "2012-02-21", "completion_date": "2017-08-27", "has_results": true, "last_update_posted_date": "2021-07-27", "last_synced_at": "2026-10-05T21:53:16.834Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01619865" }, { "nct_id": "NCT03624517", "title": "Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Esophageal Varices", "Liver Cirrhoses", "Bleeding Esophageal Varices", "Upper Gastrointestinal Bleeding" ], "interventions": [ { "name": "Octreotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2018-09-19", "completion_date": "2024-12-01", "has_results": true, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-10-05T21:53:16.834Z", "location_count": 8, "location_summary": "Jacksonville, Florida • Chicago, Illinois • Columbus, Ohio + 5 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03624517" }, { "nct_id": "NCT01121939", "title": "Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Sandostatin LAR® Depot", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2010-05", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-02-05", "last_synced_at": "2026-10-05T21:53:16.834Z", "location_count": 9, "location_summary": "Fort Myers, Florida • Orlando, Florida • Augusta, Georgia + 6 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01121939" }, { "nct_id": "NCT03571594", "title": "A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acromegaly" ], "interventions": [ { "name": "ONO-5788", "type": "DRUG" }, { "name": "ONO-5788 Placebo", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ono Pharmaceutical Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2018-06-07", "completion_date": "2019-05-16", "has_results": false, "last_update_posted_date": "2019-06-05", "last_synced_at": "2026-10-05T21:53:16.834Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03571594" }, { "nct_id": "NCT04919226", "title": "Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT", "type": "DRUG" }, { "name": "CAPTEM (Capecitabine and Temozolomide)", "type": "DRUG" }, { "name": "Amino-Acid Solution", "type": "OTHER" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ITM Solucin GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 259, "start_date": "2021-12-21", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-05T21:53:16.834Z", "location_count": 14, "location_summary": "Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04919226" }, { "nct_id": "NCT06784752", "title": "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Somatostatin Receptor Positive (SSTR+)", "Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)" ], "interventions": [ { "name": "[177Lu]Lu-DOTA-TATE", "type": "RADIATION" }, { "name": "Octreotide LAR", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "12 Years to 100 Years" }, "enrollment_count": 240, "start_date": "2025-05-30", "completion_date": "2034-01-23", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-05T21:53:16.834Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06784752" }, { "nct_id": "NCT00088582", "title": "Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acromegaly" ], "interventions": [ { "name": "Pasireotide (SOM230), Octreotide (Sandostatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 62, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-11-07", "last_synced_at": "2026-10-05T21:53:16.834Z", "location_count": 5, "location_summary": "Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088582" }, { "nct_id": "NCT00075868", "title": "Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anal Cancer", "Colorectal Cancer", "Drug/Agent Toxicity by Tissue/Organ", "Radiation Enteritis" ], "interventions": [ { "name": "octreotide acetate", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 233, "start_date": "2003-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-11-17", "last_synced_at": "2026-10-05T21:53:16.834Z", "location_count": 112, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Chico, California + 89 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chico", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075868" }, { "nct_id": "NCT01424241", "title": "Effects of Sandostatin LAR® in Acromegaly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acromegaly" ], "interventions": [ { "name": "Sandostatin LAR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2006-10", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2024-07-24", "last_synced_at": "2026-10-05T21:53:16.834Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01424241" } ] }